TheStreet lowered shares of Boston Scientific Co. (NYSE:BSX) from a b rating to a c+ rating in a report issued on Thursday morning.

Several other research firms have also weighed in on BSX. Oppenheimer Holdings Inc. set a $26.00 price objective on shares of Boston Scientific and gave the stock a hold rating in a research note on Friday, February 3rd. BTIG Research reissued a neutral rating on shares of Boston Scientific in a research note on Sunday, January 8th. Needham & Company LLC lifted their price objective on shares of Boston Scientific from $28.00 to $29.00 and gave the stock a buy rating in a research note on Thursday, February 2nd. Northland Securities restated a positive rating on shares of Boston Scientific in a report on Thursday, February 23rd. Finally, Jefferies Group LLC restated a hold rating and set a $26.00 target price on shares of Boston Scientific in a report on Friday, February 3rd. Five analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of Buy and an average price target of $26.20.

Analyst Recommendations for Boston Scientific (NYSE:BSX)

Shares of Boston Scientific (NYSE:BSX) traded down 0.04% during mid-day trading on Thursday, hitting $24.42. 691,131 shares of the stock were exchanged. Boston Scientific has a 1-year low of $17.78 and a 1-year high of $25.65. The company’s 50-day moving average is $24.81 and its 200-day moving average is $23.08. The firm has a market cap of $33.30 billion, a price-to-earnings ratio of 97.68 and a beta of 1.06.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Thursday, February 2nd. The company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.01. Boston Scientific had a net margin of 4.14% and a return on equity of 23.70%. The business had revenue of $2.19 billion for the quarter, compared to analyst estimates of $2.16 billion. During the same quarter last year, the firm earned $0.26 EPS. Boston Scientific’s quarterly revenue was up 10.8% compared to the same quarter last year. Equities research analysts anticipate that Boston Scientific will post $1.24 earnings per share for the current fiscal year.

Your IP Address:

In related news, EVP Keith D. Dawkins sold 80,783 shares of the firm’s stock in a transaction on Tuesday, February 7th. The shares were sold at an average price of $25.21, for a total value of $2,036,539.43. Following the completion of the transaction, the executive vice president now directly owns 75,864 shares of the company’s stock, valued at $1,912,531.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Timothy A. Pratt sold 6,195 shares of the firm’s stock in a transaction on Monday, January 9th. The shares were sold at an average price of $22.24, for a total transaction of $137,776.80. Following the completion of the transaction, the executive vice president now directly owns 231,273 shares of the company’s stock, valued at $5,143,511.52. The disclosure for this sale can be found here. Insiders sold 154,011 shares of company stock worth $3,821,067 over the last quarter. 1.31% of the stock is owned by corporate insiders.

Several institutional investors have recently added to or reduced their stakes in BSX. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Boston Scientific by 14.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 613,289 shares of the company’s stock valued at $14,596,000 after buying an additional 75,768 shares in the last quarter. Quadrature Capital Ltd purchased a new position in Boston Scientific during the third quarter valued at $9,577,000. Synovus Financial Corp purchased a new position in Boston Scientific during the third quarter valued at $102,000. Mirae Asset Global Investments Co. Ltd. boosted its position in Boston Scientific by 16.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 157,099 shares of the company’s stock valued at $3,739,000 after buying an additional 21,814 shares in the last quarter. Finally, Tredje AP fonden boosted its position in Boston Scientific by 3.3% in the fourth quarter. Tredje AP fonden now owns 154,272 shares of the company’s stock valued at $3,337,000 after buying an additional 4,996 shares in the last quarter. 91.70% of the stock is owned by institutional investors and hedge funds.

About Boston Scientific

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

5 Day Chart for NYSE:BSX

Receive News & Ratings for Boston Scientific Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.